Drug intelligence / Profile preview

AG01

Development stage: Phase 1
Lead developer: A&G Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

AG01 is a recombinant human monoclonal antibody that targets progranulin (PGRN; also known as glycoprotein 88 or GP88), a protein overexpressed in various cancers. By binding to PGRN on cancer cells, AG01 inhibits its function and may exert antineoplastic effects. The drug is being developed for the treatment of advanced solid tumors, including triple-negative breast cancer and hormone-refractory breast cancer. It is currently in Phase 1 clinical trials as a first-in-human therapy for these indications[1][2][3].

Other names: anti-progranulin monoclonal antibody AG01anti-progranulin/GP88 antibodyPGRN inhibitor AG-01

Targets

GRN (Progranulin)

Beyond the preview

Go deeper on AG01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AG01.

Explore the full profile